Pembrolizumab-induced CNS vasculitis: Neurologic adverse events due to checkpoint inhibitors

Abstract

Early recognition of potential neurologic manifestations of immune-mediated adverse events in immune checkpoint inhibitor–treated patients can lead to prompt treatments and improved outcomes. Alternative or concurrent diagnosis should be also considered if symptoms and/or disease course are atypical.